NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson has decided to discontinue the Autonomy study as a scheduled review found posdinemab did not achieve statistical significance in slowing clinical decline. The Autonomy proof-of-concept study was a first-of-its-kind precision approach to evaluating targeted intervention in early Alzheimer's disease.
The company said the initial findings underscore the deep complexity of the disease. Johnson & Johnson said it remains committed to transforming the future of Alzheimer's care and is confident in its pipeline of therapies to treat the broad spectrum of disease.
For More Such Health News, visit rttnews.com.
Copyright(c) 2025 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2025 AFX News
